IP Library Granted Patent US 9,387,199
Granted Patent B2
US 9,387,199 · App. 14/539,214 · Granted Jul 12, 2016

Compositions and methods for treating clostridium infection and preventing recurrence of infection

Inventors: Richard L. Guerrant (Charlottesville, VA); Cirle Alcantara Warren (Waynesboro, VA); John Hudson Moore, II (Richmond, VA); Edward van Opstal (Great Falls, VA)
Assignee: University of Virginia Patent Foundation
A61K31/4188A61K31/4174A61K31/426A61K31/7028A61K38/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,387,199
App. No.
14/539,214
Granted
Jul 12, 2016
Kind
B2
Abstract

C. difficile infection (CDI) is the most common cause of antibiotic-associated diarrhea. Unfortunately, antibiotic therapy remains as the standard treatment for this antibiotic-induced disease and relapses are common. Antibiotic treatment typically is given for 10 to 14 days for initial or second episode of CDI. For recurrent episodes, more prolonged courses are recommended. It is disclosed herein that lower dose or shorter course of the antimicrobial treatment is sufficient to treat the disease and prevent recurrent disease by enabling a good immunologic response to infection, and perhaps also by better preserving normal flora, thus protecting against relapses or reinfection.

Claims (7)

1. A method of treating a C. difficile infection in a subject using a short-term course of antibiotic treatment, said method comprising administering to said subject a pharmaceutical composition comprising an antibiotic effective against C. difficile , wherein said antibiotic is selected from the group consisting of vancomycin, fidaxomicin, metronidazole, and nitazoxanide, wherein said antibiotic is administered at a dosage ranging from about 0.1 mg/kg/day to about 20 mg/kg/day and said course of antibiotic treatment is selected from the group consisting of 1, 2, 3 and 4 days, thereby treating the C. difficile infection in said subject using said short term course of antibiotic treatment.

2. The method of claim 1 , wherein said short-term course of antibiotic treatment is 3 or 4 days.

3. The method of claim 1 , wherein said short-term course of antibiotic treatment is 1 or 2 days.

4. The method of claim 1 , wherein said antibiotic is administered at a dosage ranging from 0.5 mg/kg/day to 20 mg/kg/day.

5. The method of claim 1 , wherein said antibiotic is administered at a dosage selected from the group consisting of 0.1, 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0, 10, and 15 mg/kg/day.

6. The method of claim 1 , wherein said method controls diarrhea and weight loss.

7. The method of claim 1 , wherein said method reduces recurrent infection.

Assignments (1)
CONFIRMATORY LICENSE Recorded Dec 8, 2014
From: UNIVERSITY OF VIRGINIA PATENT FOUNDATION D.B.A. UNIVERSITY OF VIRGINIA LICENSING AND VENTURES GROUP
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 034537/0779 →
Continuity (2)
Provisional Application 61902842 · Nov 12, 2013
Related Publication 20150133366A1 · May 14, 2015